Pfizer 3Q profit falls 14 pct on generic Lipitor (Update)

November 1, 2012 by Linda A. Johnson

(AP)—Drug giant Pfizer Inc. said Thursday that its third-quarter profit fell 14 percent as sales plunged, mainly due to U.S. generic competition to cholesterol fighter Lipitor, long the world's top-selling drug.

Sales of Lipitor, which is still under patent in some other countries, dropped 71 percent worldwide to $749 million and nosedived 87 percent in the U.S.

It had plenty of company: Sales for more than two-thirds of Pfizer's medicines declined, most by 10 percent or more and mainly because of generic competition. That cut prescription drug revenue by about $2 billion.

But even Prevnar 13, a shot against ear infections, deadly meningitis and other bacterial diseases that is the top-selling vaccine in history, saw sales fall by 12 percent, to $868 million. It's still protected by patents, so the drop could indicate that sales have hit a wall as most children in developing countries have already been vaccinated.

The New York-based maker of pain reliever Lyrica said net income was $3.21 billion, or 43 cents per share. That was down from $3.74 billion, or 48 cents per share, a year earlier.

Excluding one-time items, earnings were 53 cents per share. Analysts expected 52 cents. The items included a $1.1 billion gain from a tax settlement, a $491 million charge related to an agreement with the U.S. Justice Department to end an investigation into past promotion of the immunosuppressant drug Rapamune for unapproved uses, and other charges for restructuring, productivity initiatives and the gradual writedown in the value of some assets.

Revenue fell 16 percent to $13.98 billion, well below expectations for $14.66 billion. Unfavorable exchange rates cut worldwide revenue by 4 percent. Excluding the currency impact, total international sales fell 7 percent, to $8.35 billion. U.S. sales dropped 18 percent, to $5.63 billion.

Revenue from prescription drugs dropped 18 percent, to $12.12 billion, as four of its five segments fared poorly. Sales were down sharply for primary care and specialty care medicines and down by a percent or two for cancer drugs and drugs sold in emerging markets such as China and India. Only the established products business, which sells popular but off-patent medicines, saw sales rise, by 7 percent to $2.4 billion—and that was because sales of Lipitor in the U.S. and Japan were shifted to that category from primary care sales.

Lipitor, which once brought in as much as $13 billion a year, got generic competition on Nov. 30, 2011. Pfizer slowed defections while it had limited, slightly cheaper generic competition through May, with big rebates to insurers and $4 copayment offers for most patients staying on Lipitor. But prices plunged when multiple generics hit the market at the end of May. Pfizer then ended the insurer rebates and most patients switched to generics.

The bright spots were increases of 14 percent to $1.04 billion for what's now Pfizer's top seller, Lyrica for fibromyalgia and other pain; 5 percent for painkiller Celebrex, to $676 million, and 5 percent for erectile dysfunction drug Viagra, to $517 million.

Sales of consumer health products such as pain relievers Advil and Anbesol increased 2 percent to $780 million, helped by two small acquisitions. Veterinary medicine sales, including the Convenia antibiotic for dogs and cats, fell by 2 percent to $1.02 billion.

Despite the lower sales, Pfizer raised its 2012 profit forecast, to $1.30 to $1.38 per share, from $1.21 to $1.36 per share. But the company reduced the top end of its revenue forecast by $1 billion. The new forecast is for $58 billion to $59 billion.

CEO Ian Read noted three new drugs have recently been approved in the U.S. or Europe, and two others that could be big sellers could get approved soon.

"Given our demonstrated ability to advance our strategic initiatives, I believe we are well-positioned to deliver attractive returns for our shareholders over time," Read said in a statement.

The company noted its board of directors has authorized a new $10 billion share repurchase program that's to start when Pfizer completes the pending sale of its nutrition business for $11.85 billion to Swiss food and drink giant Nestle SA. That's expected to happen in the next few months.

The company has bought back about 302 million shares in the past 12 months, reducing the total outstanding to 7.5 billion, and has another $4.1 billion remaining under its current buyback program.

Pfizer's stock fell 28 cents, or 1.1 percent, at $24.56 in premarket trading.

Explore further: Pfizer 2Q net income rises 25 pct on lower costs

shares

Related Stories

Pfizer 2Q net income rises 25 pct on lower costs

July 31, 2012
Drugmaker Pfizer Inc.'s second-quarter net income jumped 25 percent as sharply lower costs for production, marketing and restructuring more than offset a plunge in revenue from cholesterol fighter Lipitor due to increasing ...

Retailers sue Pfizer, charge generic Lipitor delay

July 7, 2012
(AP) — Five large U.S. drug and grocery chains are suing Pfizer Inc. and a second drugmaker, alleging they conspired to delay sales of cheap generic versions of the blockbuster cholesterol drug Lipitor.

Merck's 2Q net falls on charges, but sales rise

July 27, 2012
Merck & Co.'s second-quarter net income fell 11.4 percent as slightly higher sales were offset by acquisition and restructuring costs. However, the drugmaker beat Wall Street expectations, and Merck shares jumped in early ...

J&J Q3 net income drops 7 percent on higher costs

October 16, 2012
Johnson & Johnson's third-quarter profit fell 7 percent as increased research and production costs offset higher sales for its medicines and medical devices and new revenue from its biggest acquisition ever.

With new generic rivals, Lipitor's sales halved

December 20, 2011
Sales of cholesterol blockbuster Lipitor plunged by half barely a week after the world's top-selling drug got its first U.S. generic competition, new data show.

Recommended for you

Drug therapy from lethal bacteria could reduce kidney transplant rejection

August 3, 2017
An experimental treatment derived from a potentially deadly microorganism may provide lifesaving help for kidney transplant patients, according to an international study led by investigators at Cedars-Sinai.

Exploring the potential of human echolocation

June 25, 2017
People who are visually impaired will often use a cane to feel out their surroundings. With training and practice, people can learn to use the pitch, loudness and timbre of echoes from the cane or other sounds to navigate ...

Team eradicates hepatitis C in 10 patients following lifesaving transplants from infected donors

April 30, 2017
Ten patients at Penn Medicine have been cured of the Hepatitis C virus (HCV) following lifesaving kidney transplants from deceased donors who were infected with the disease. The findings point to new strategies for increasing ...

'bench to bedside to bench': Scientists call for closer basic-clinical collaborations

March 24, 2017
In the era of genome sequencing, it's time to update the old "bench-to-bedside" shorthand for how basic research discoveries inform clinical practice, researchers from The Jackson Laboratory (JAX), National Human Genome Research ...

The ethics of tracking athletes' biometric data

January 18, 2017
(Medical Xpress)—Whether it is a FitBit or a heart rate monitor, biometric technologies have become household devices. Professional sports leagues use some of the most technologically advanced biodata tracking systems to ...

Financial ties between researchers and drug industry linked to positive trial results

January 18, 2017
Financial ties between researchers and companies that make the drugs they are studying are independently associated with positive trial results, suggesting bias in the evidence base, concludes a study published by The BMJ ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.